Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2018, XLIV/260: 075-081 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2018, XLIV/260: 075-081

Title: Proteflazid®: Clinical experience in children of young and preschool age – systematic review of postmarketing surveillance 

Authors: Beketova G, Grynevych O, Solomakha L, Golovnia N. 

More details

08/260

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN ENGLISH.

Proteflazid®: Clinical experience in children of young and preschool age – systematic review of postmarketing surveillance


Beketova G1, Grynevych O2, Solomakha L2, Golovnia N1.

1Shupyk National Medical Academy for Post-graduate Education, Kyiv, Ukraine; 2Scientific & Manufacturing Company “Ecopharm” Ltd, Kyiv, Ukraine

Scientific literature data on the experience of use of Proteflazid® (drops) and Immunoflazid® (syrup) for the treatment of viral diseases in children of the first six years of life are analysed in the article. A systematic review was conducted on the basis of postmarketing comparative clinical trials and long-term follow-up (during the period of 2002 to 2016) that involved about 1500 children (the intent-to-treat population comprised more than 800 of them). The safety and efficacy of the Proteflazid® (drops) and Immunoflazid® (syrup) usage in children for the treatment of viral infections have been proven.

Key words: Proteflazid®, Immunoflazid®, herpetic infections, ARVI, treatment, children

Pol Med J, 2018; XLIV (260); 75–81